A case-control study of 174,000 individuals found that use of metformin was associated with a reduced odds of developing wet, age-related macular degeneration.
US FDA approved a higher-dose version of Regeneron Pharmaceuticals drug Eylea for treatment of a disease that is a leading cause of blindness among the elderly, the company said in a statement.
Phase 3 registration trials found the comparability of two biosimilars to reference aflibercept in terms of efficacy, safety, pharmacokinetics, and immunogenicity.
US health regulators on Tuesday declined to approve a higher-dose version of Regeneron s drug Eylea for treatment of a disease that is leading cause of blindness among the elderly.